Rani Therapeutics Holdings, Inc.
RANI
$1.10
$0.00010.01%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -2.93% | -12.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.01% | -5.79% | |||
| Operating Income | 4.70% | 5.79% | |||
| Income Before Tax | -23.58% | 4.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.58% | 4.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 14.08% | -9.41% | |||
| Net Income | -31.90% | 0.32% | |||
| EBIT | 4.70% | 5.79% | |||
| EBITDA | 4.87% | 5.94% | |||
| EPS Basic | -16.37% | 9.01% | |||
| Normalized Basic EPS | 68.05% | -2.35% | |||
| EPS Diluted | -16.37% | 9.01% | |||
| Normalized Diluted EPS | 68.05% | -2.35% | |||
| Average Basic Shares Outstanding | 13.37% | 9.54% | |||
| Average Diluted Shares Outstanding | 13.37% | 9.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||